Long-term Outcomes of MCP Surface Replacement Arthroplasty in Patients With Rheumatoid Arthritis

• Published in: Hand (New York, N.Y.) N.Y.), 2022-03, Vol.17 (2), p.271-277
• Main Authors: Claxton, Matthew R., Wagner, Eric R., Rizzo, Marco
• Format: Article
• Language: English
• Subjects: Arthritis, Rheumatoid - surgery; Arthroplasty, Replacement; Humans; Joint Prosthesis; Metacarpophalangeal Joint - surgery; Range of Motion, Articular; Surgery
• ISSN: 1558-9447; 1558-9455
• DOI: 10.1177/1558944720926631

Background: Surface replacement arthroplasty (SRA) can be used in the treatment of rheumatoid arthritis (RA) affecting the metacarpophalangeal (MCP) joint. The authors of this study sought to investigate the outcomes of MCP SRA in patients with RA. Methods: Retrospective review of medical records and an institutional joint registry were used to gather data on 80 MCP SRAs performed in 27 patients with RA. Data collected included demographics, SRA revisions, reoperations, complications, pain, and MCP arc of motion. Results: The mean postoperative follow-up was 9.5 years (range, 2.1-20.5 years), with all SRAs achieving at least 2 years of follow-up. Thirteen digits (16%) underwent revision arthroplasty, and 29 (36%) required reoperation. The 5-, 10-, 15-, and 20-year rates of survival from implant revision were 95%, 85%, 80%, and 69%, respectively. The 5-, 10-, 15-, and 20-year rates of survival from overall reoperation were 80%, 65%, 55%, and 46%, respectively. Metacarpophalangeal joint arc of motion, grip strength, and pain levels significantly improved following surgery. Conclusions: Metacarpophalangeal SRA can offer benefit to patients with RA for improvement in function and pain. High overall reoperation rates remain concerning; however, most do not involve arthroplasty revision.